| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8435351 | Cancer Letters | 2016 | 10 Pages |
Abstract
Phase III trials in advanced gastric cancer have demonstrated improved outcome with ramucirumab as second-line treatment. Most of the other studies on anti-angiogenic agents in gastric cancer have reported improvement in response rate but not in OS compared to chemotherapy alone. Future research is expected in optimizing the anti-angiogenic therapy combined with traditional treatment.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fei Shan, Rulin Miao, Kan Xue, Zhemin Li, Ziyu Li, Zhaode Bu, Aiwen Wu, Lianhai Zhang, Xiaojiang Wu, Xianglong Zong, Xiaohong Wang, Shuangxi Li, Xin Ji, Ziyu Jia, Ziran Li, Jiafu Ji,